Adezmapimod 50 mg | 99.79%
TargetMol
Adezmapimod (PB 203580) is a p38 MAPK inhibitor (IC50: 0.3-0.5 μM). It shows more than 100-fold selectivity over PKB, LCK, and GSK-3β.
More Information Supplier PageAdezmapimod
Search Results
Anagrelide hydrochloride 50 mg | Purity Not Available
TargetMol
Anagrelide hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis.
More Information Supplier PageAnagrelide hydrochloride
Ginkgolide B 25 mg | 99.39%
TargetMol
Ginkgolide B is a PAFR antagonist(IC50=3.6 μM) isolated from Ginkgo biloba.
More Information Supplier PageGinkgolide B
Rhamnose 100 mg | 99.77%
TargetMol
Addition of the Rhamnose-rich polysaccharide, RROP-1, to normal human dermal fibroblasts (NHDFs) and human endothelial cells produced a dose-dependent stimulation of the calcium-signaling pathway, inducing fast and transient increases in Ca2 influx and intracellular free Ca2 level.
More Information Supplier PageRhamnose
Anagrelide hydrochloride 25 mg | Purity Not Available
TargetMol
Anagrelide hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis.
More Information Supplier PageAnagrelide hydrochloride
Anagrelide hydrochloride 200 mg | Purity Not Available
TargetMol
Anagrelide hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis.
More Information Supplier PageJZL195 10 mg | 99.78%
TargetMol
JZL195
JZL195 5 mg | 99.78%
TargetMol
JZL195
Stattic 100 mg | 99.64%
TargetMol
Stattic is a small molecule inhibitor of STAT3. It selectively inhibits STAT3 activation, dimerization, and nuclear translocation (IC50: 5.1 μM).
More Information Supplier PageStattic
Stattic 10 mg | 99.64%
TargetMol
Stattic is a small molecule inhibitor of STAT3. It selectively inhibits STAT3 activation, dimerization, and nuclear translocation (IC50: 5.1 μM).
More Information Supplier PageStattic